SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q3 2023 vs. Q2 2023
How the institutions holding SAB Biotherapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 38 | 34 | −4 |
| Shares | 3.96M | 3.82M | −134.7K (−3.4%) |
| Value | $3.28M | $2.41M | −$872.0K (−26.5%) |
New holders (3)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pathstone Family Office, LLC | 506,513 | $319.1K | 0.00% |
| FMR LLC | 343 | $216 | 0.00% |
| Qube Research & Technologies Ltd | 69 | $43 | 0.00% |
Sold out (7)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Veritable, L.P. | 506,513 | $420.4K |
| Bridgeway Capital Management, LLC | 84,000 | $69.7K |
| Silver Oak Securities, Inc | 51,891 | $43.0K |
| Prudential Financial Inc | 36,200 | $30.0K |
| Virtu Financial LLC | 24,897 | $21.0K |
| Two Sigma Investments, LP | 25,094 | $20.8K |
| Two Sigma Securities, LLC | 12,865 | $10.7K |